Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Shares Traded Last Trade
  1.20 3.75% 33.20 2,275,995 16:35:01
Bid Price Offer Price High Price Low Price Open Price
33.00 34.00 33.50 31.50 31.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.07 -16.91 -26.80 28
Last Trade Time Trade Type Trade Size Trade Price Currency
17:09:08 O 50,000 33.00 GBX

Diurnal (DNL) Latest News

More Diurnal News
Diurnal Takeover Rumours

Diurnal (DNL) Share Charts

1 Year Diurnal Chart

1 Year Diurnal Chart

1 Month Diurnal Chart

1 Month Diurnal Chart

Intraday Diurnal Chart

Intraday Diurnal Chart

Diurnal (DNL) Discussions and Chat

Diurnal Forums and Chat

Date Time Title Posts
19/7/201915:00Diurnal (MC Ј25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP10
12/7/201911:20Diurnal Group plc187

Add a New Thread

Diurnal (DNL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-19 17:36:3833.0050,00016,500.00O
2019-07-19 17:02:1733.8250,00016,910.00O
2019-07-19 16:36:2533.0021,5977,127.01O
2019-07-19 16:19:4833.2021,3737,095.84O
2019-07-19 16:09:0833.20105,00034,860.00O
View all Diurnal trades in real-time

Diurnal (DNL) Top Chat Posts

Diurnal Daily Update: Diurnal Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DNL. The last closing price for Diurnal was 32p.
Diurnal Group Plc has a 4 week average price of 26.50p and a 12 week average price of 25.50p.
The 1 year high share price is 180p while the 1 year low share price is currently 21.50p.
There are currently 84,639,001 shares in issue and the average daily traded volume is 313,307 shares. The market capitalisation of Diurnal Group Plc is £28,100,148.33.
costax1654x: From LSE: 225p Valuation!I must say this report sums up the situation very well, massive upside from here - 765% to be precise (225p target vs 26p current)."Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL's first two products alone equates to £248m. Risk- adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.""Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for a regulatory submission later this year. The share price also reflects the fact that the company will require more capital in 2019 in the absence of any significant licensing deals. DNL's US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator."
Diurnal share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190720 07:53:56